Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial

Published: 2018-02-21 16:28:00
Updated: 2018-02-21 16:46:09

They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm.

A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase III patient registration for ‘Oraxol,’ the Hanmi Pharm’s new anticancer drug whi...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.